Vanda Net Income From Continuing Ops from 2010 to 2026

VNDA Stock  USD 8.91  0.31  3.60%   
Vanda Pharmaceuticals' Net Loss is decreasing over the years with slightly volatile fluctuation. Overall, Net Loss is projected to go to about -209.5 M this year. From 2010 to 2026 Vanda Pharmaceuticals Net Loss quarterly data regression line had arithmetic mean of (20,865,547) and r-squared of  0.14. View All Fundamentals
 
Net Loss  
First Reported
2004-12-31
Previous Quarter
-22.6 M
Current Value
-141.2 M
Quarterly Volatility
21.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Vanda Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vanda Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 M, Interest Expense of 6 M or Total Revenue of 147.2 M, as well as many indicators such as Price To Sales Ratio of 2.28, Dividend Yield of 0.0 or PTB Ratio of 1.51. Vanda financial statements analysis is a perfect complement when working with Vanda Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Vanda Stock
Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
Analyzing Vanda Pharmaceuticals's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Vanda Pharmaceuticals's current valuation and future prospects.

Latest Vanda Pharmaceuticals' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Vanda Pharmaceuticals over the last few years. It is Vanda Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vanda Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Vanda Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(20,865,547)
Geometric Mean26,690,458
Coefficient Of Variation(388.61)
Mean Deviation48,742,484
Median(9,802,000)
Standard Deviation81,085,326
Sample Variance6574.8T
Range336M
R-Value(0.38)
Mean Square Error6007.8T
R-Squared0.14
Significance0.13
Slope(6,079,668)
Total Sum of Squares105197.3T

Vanda Net Income From Continuing Ops History

2026-209.5 M
2025-220.5 M
2024-18.9 M
202311.8 M
20226.3 M
202133.2 M
202023.3 M

About Vanda Pharmaceuticals Financial Statements

Vanda Pharmaceuticals stakeholders use historical fundamental indicators, such as Vanda Pharmaceuticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Vanda Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vanda Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Vanda Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vanda Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-220.5 M-209.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vanda Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vanda Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vanda Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vanda Pharmaceuticals Stock:
Check out the analysis of Vanda Pharmaceuticals Correlation against competitors.
For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vanda Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.96)
Earnings Share
(3.74)
Revenue Per Share
3.667
Quarterly Revenue Growth
0.076
Return On Assets
(0.17)
Understanding Vanda Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Vanda's accounting equity. The concept of intrinsic value - what Vanda Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Vanda Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vanda Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.